New Partnership Connects Leadership Excellence to Improved Post-Acute Care 
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety...
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered...
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish...
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer...
OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
Issues 2024 financial guidanceWARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a...
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
Robert M. Brenner Robert M. Brenner, M.D., Chief Medical Officer William D. Turner William D. Turner, Chief Development Officer BRISBANE,...
Alignment Healthcare Delivers 44% Year-Over-Year Membership Growth Following Significant Boost from AEP, Increasing Membership to 155,500
Company provides year-end health plan membership guidance, strengthens conviction of path to adjusted EBITDA breakeven in 2024ORANGE, Calif., Jan. 08,...
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of...
Nuclear Medicine/ Radiopharmaceutical/Logistic – Loos, France, RLG, Isovital Headquarter, Jan 8th 2024 : “Life Couriers acquires Isovital and the RLG group to create the global logistic leader for radiopharmaceuticals transportation”.
“Life Couriers acquires RLG to create the global logistic leader for radiopharmaceuticals transportation”. Philippe Sueur, Isovital President stated: « Significant efforts were...
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024...
Stryker announces 2023 sales surpassed $20 billion
Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales...
Mesa Laboratories Appoints Mark Capone to its Board of Directors
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader...
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative ColitisNEW...
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer...
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net...
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of...
LifeMD Provides 2024 Financial Guidance
Revenue expected to be between $195 and $205 million, represents a 31% to 38% increase over the midpoint of 2023...
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase...
Affimed Announces Leadership Change and Organizational Restructuring
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount...
Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets
Leading Investors BOLD Capital, Digitalis Ventures, and Hill Creek Partners drive financial milestone Financing to expedite conditional FDA approval of...